Deltex Medical : Interim Results Presentation 2022

Deltex Medical Group plc

Results to 30 June 2022 & update on progress

September 2022

Andy Mears

Chief Executive Officer

Natalie Wettler

Group Finance Director

© Deltex Medical Group plc (2022). All rights reserved.

Real-time oesophageal Doppler haemodynamic monitoring:

improves patient outcomes; increases hospital throughput

Disclaimer

The information contained in this document ("Presentation") and the presentation made to you verbally has been prepared by Deltex Medical Group plc (the "Company"). Deltex Medical Group plc is a UK company quoted on AIM, a market operated by London Stock Exchange plc. This Presentation has not been fully verified and is subject to material updating, revision and further verification and amendment without notice. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (as amended) ("FSMA") and therefore it is being provided for information purposes only.

While the information contained herein has been prepared in good faith, neither the Company nor any of its directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

The views of the Company's management/directors and/or its partners set out in this document could ultimately prove to be incorrect. No warranty, express or implied, is given by the presentation of these figures herein and investors should place no reliance on the Company's estimates cited in this document.

This Presentation may contain "forward-looking statements" that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, performance, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements are not guarantees of future performance of the Company and reflect assumptions and subjective judgements by the Company that are difficult to predict, qualify and/or quantify. These forward-looking statements speak only as of the date of this Presentation and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation.

This Presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute or form part of any offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in these slides or the Presentation or on the completeness, accuracy or fairness thereof. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

The distribution of this document in or to persons subject to jurisdictions outside the UK may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

Allenby Capital Limited ("Allenby Capital"), which is authorised and regulated by the Financial Conduct Authority, is acting as the nominated adviser and broker to the Company. Accordingly, the recipients should note that Allenby Capital is neither advising nor treating as a client any other person and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Allenby Capital and nor for providing advice in relation to the matters contained in this Presentation.

2

Deltex Medical

Real-time oesophageal Doppler haemodynamic monitoring:

improves patient outcomes; increases hospital throughput

Deltex Medical - key drivers for the Group

New products:

2022 next gen. monitor launch: expand the reach of DEMG's technology throughout the in-hospital patient journey, plus generate immediate capital replacement revenues

Accessible market:

As Covid transitions to endemic, hospital access improves and surgical activity increases to clear backlogs, revenues starting to grow

Release of the next generation TrueVue monitor later this year:

• will be configured for single-use high margin disposables generating strong positive cash flows
• will include the addition of an innovative new non-invasive device for the rapid triage for severe disease - i.e. sepsis
• will ultimately be used in much broader applications both inside and outside the hospital
• TrueVue Doppler has been proven to reduce post-operative complications and is supported by 24 Randomised Clinical Trials (RCTs)
• the new, non-invasive technology will be able to rapidly assess the severity of disease for the in-hospital awake patient; this would include the rapid triage of a Covid patient presenting to the hospital
• improved access to hospitals for sales teams and clinical educators is key to driving growth

3

Deltex Medical

Real-time oesophageal Doppler haemodynamic monitoring:

improves patient outcomes; increases hospital throughput

Summary P&L information to 30 June, 2022

£000 (unaudited)	H1 2022		H1 2021
Probe revenues	911	79%	923	86%
Other revenues	247	21%	149	14%
Total revenues	1,158	100%	1,072	100%
Gross margin	852			691	64%
	74%
Administrative costs	(779)			(777)
Sales & distribution costs	(554)			(466)
R&D and Q&R costs	(120)			(117)
Total overheads	(1,453)			(1,360)
Adjusted EBITDA*	(418)			(242)
Loss for the period	(662)			(524)

Return to growth: revenues up 8% to £1.2M

International division revenues up 39%

Gross margin back up to 74%

4	Deltex Medical
* Earnings before interest, tax, depreciation and amortisation, share-based payments, non-executive directors' fees and any exceptional items

Real-time oesophageal Doppler haemodynamic monitoring:

improves patient outcomes; increases hospital throughput

Summary balance sheet information at 30 June 2022

£000	30 June		30 June
	2022		2021
Property, plant &	274	271
equipment
Intangible assets	3,419	2,756
Financial assets at	171	157
amortised cost

Non-current assets	3,864	3,184
Inventories	835	812
Trade receivables	540	392
Other current assets	206	212
Cash	611	553
Current assets	2,192	1,969
Total assets	6,056	5,153

		30 June		30 June
		2022		2021
Borrowings	(700)	(163)
Trade & other payables	(1,419)	(1,527)
Current liabilities	(2,119)	(1,690)
Borrowings	(1,048)	(1,010)
Trade & other payables	(203)	(252)
Provisions	(60)	(51)
Non-current liabilities	(1,311)	(1,313)
Total liabilities	(3,430)	(3,003)

Net assets	2,626	2,150

5

Deltex Medical